Jermie E Cozart
Examiner (ID: 17502, Phone: (571)272-4528 , Office: P/3726 )
Most Active Art Unit | 3726 |
Art Unit(s) | 3728, 3799, 3726 |
Total Applications | 2110 |
Issued Applications | 1676 |
Pending Applications | 108 |
Abandoned Applications | 326 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 19338505
[patent_doc_number] => 12048676
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Agents for reversing toxic proteinopathies
[patent_app_type] => utility
[patent_app_number] => 17/494830
[patent_app_country] => US
[patent_app_date] => 2021-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 66
[patent_figures_cnt] => 120
[patent_no_of_words] => 46150
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494830
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/494830 | Agents for reversing toxic proteinopathies | Oct 5, 2021 | Issued |
Array
(
[id] => 17426725
[patent_doc_number] => 20220054433
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => AGENTS FOR REVERSING TOXIC PROTEINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 17/494824
[patent_app_country] => US
[patent_app_date] => 2021-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46016
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494824
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/494824 | Agents for reversing toxic proteinopathies | Oct 4, 2021 | Issued |
Array
(
[id] => 17312803
[patent_doc_number] => 20210401851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => PAR-4 AGONISTS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/470475
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470475
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/470475 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER | Sep 8, 2021 | Abandoned |
Array
(
[id] => 17258436
[patent_doc_number] => 20210371421
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => NOVEL COMPOUNDS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/405736
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7565
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 193
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405736
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/405736 | Compounds and methods | Aug 17, 2021 | Issued |
Array
(
[id] => 17921544
[patent_doc_number] => 11464765
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-11
[patent_title] => Use of an N-substituted pyridyl benzisoselazolone compound
[patent_app_type] => utility
[patent_app_number] => 17/402006
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 2979
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402006
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/402006 | Use of an N-substituted pyridyl benzisoselazolone compound | Aug 12, 2021 | Issued |
Array
(
[id] => 17670932
[patent_doc_number] => 20220184099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => METHODS OF USING OBETICHOLIC ACID
[patent_app_type] => utility
[patent_app_number] => 17/384555
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17384555
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/384555 | METHODS OF USING OBETICHOLIC ACID | Jul 22, 2021 | Abandoned |
Array
(
[id] => 17451797
[patent_doc_number] => 11266632
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-03-08
[patent_title] => Maslinic and oleanolic acids derivatives for treating SARS-CoV-2 infection
[patent_app_type] => utility
[patent_app_number] => 17/380325
[patent_app_country] => US
[patent_app_date] => 2021-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 68
[patent_no_of_words] => 11651
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 210
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17380325
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/380325 | Maslinic and oleanolic acids derivatives for treating SARS-CoV-2 infection | Jul 19, 2021 | Issued |
Array
(
[id] => 17290883
[patent_doc_number] => 20210386722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => Treatment of Covid-19 with Nitroxides
[patent_app_type] => utility
[patent_app_number] => 17/354068
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2977
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17354068
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/354068 | Treatment of Covid-19 with Nitroxides | Jul 8, 2021 | Abandoned |
Array
(
[id] => 17227037
[patent_doc_number] => 20210353593
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN
[patent_app_type] => utility
[patent_app_number] => 17/363604
[patent_app_country] => US
[patent_app_date] => 2021-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70314
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363604
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/363604 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Jun 29, 2021 | Abandoned |
Array
(
[id] => 18886423
[patent_doc_number] => 11865179
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-09
[patent_title] => Progesterone formulations having a desirable PK profile
[patent_app_type] => utility
[patent_app_number] => 17/348140
[patent_app_country] => US
[patent_app_date] => 2021-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 22754
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17348140
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/348140 | Progesterone formulations having a desirable PK profile | Jun 14, 2021 | Issued |
Array
(
[id] => 17141634
[patent_doc_number] => 20210309646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/345064
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22817
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17345064
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/345064 | Diacylglycerol acyl transferase 2 inhibitors | Jun 10, 2021 | Issued |
Array
(
[id] => 17480498
[patent_doc_number] => 20220088002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => METHOD AGAINST CORONAVIRUS INFECTION WITH QUINOLINE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/333303
[patent_app_country] => US
[patent_app_date] => 2021-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333303
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/333303 | METHOD AGAINST CORONAVIRUS INFECTION WITH QUINOLINE COMPOUND | May 27, 2021 | Abandoned |
Array
(
[id] => 17554890
[patent_doc_number] => 11311547
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Antiviral prodrugs and nanoformulations thereof
[patent_app_type] => utility
[patent_app_number] => 17/303229
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 11
[patent_no_of_words] => 20316
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17303229
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/303229 | Antiviral prodrugs and nanoformulations thereof | May 23, 2021 | Issued |
Array
(
[id] => 17080529
[patent_doc_number] => 20210275535
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/303228
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20305
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17303228
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/303228 | Antiviral prodrugs and nanoformulations thereof | May 23, 2021 | Issued |
Array
(
[id] => 17405990
[patent_doc_number] => 11246850
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-15
[patent_title] => Methods of treating multiple sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/321788
[patent_app_country] => US
[patent_app_date] => 2021-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 49674
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17321788
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/321788 | Methods of treating multiple sclerosis | May 16, 2021 | Issued |
Array
(
[id] => 18799996
[patent_doc_number] => 11833140
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-05
[patent_title] => Compositions and methods for treating, ameliorating and preventing
[patent_app_type] => utility
[patent_app_number] => 17/306928
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18557
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306928
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/306928 | Compositions and methods for treating, ameliorating and preventing | May 2, 2021 | Issued |
Array
(
[id] => 17426756
[patent_doc_number] => 20220054464
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/233830
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17942
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233830
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/233830 | Compounds and methods for treating viral infections | Apr 18, 2021 | Issued |
Array
(
[id] => 17020826
[patent_doc_number] => 20210244697
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => COMPOSITIONS COMPRISING 15-OHEPA AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/232862
[patent_app_country] => US
[patent_app_date] => 2021-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5018
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17232862
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/232862 | COMPOSITIONS COMPRISING 15-OHEPA AND METHODS OF USING THE SAME | Apr 15, 2021 | Abandoned |
Array
(
[id] => 16991725
[patent_doc_number] => 20210230145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => METHODS OF TREATING INFLAMMATION OR NEUROPATHIC PAIN
[patent_app_type] => utility
[patent_app_number] => 17/227072
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48374
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -60
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227072
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/227072 | METHODS OF TREATING INFLAMMATION OR NEUROPATHIC PAIN | Apr 8, 2021 | Abandoned |
Array
(
[id] => 18412035
[patent_doc_number] => 11666562
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Ilaprazole for inhibiting the release of enveloped viruses from cells
[patent_app_type] => utility
[patent_app_number] => 17/301454
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 8
[patent_no_of_words] => 14072
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301454
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/301454 | Ilaprazole for inhibiting the release of enveloped viruses from cells | Apr 1, 2021 | Issued |